Health · Pharma & Biotech · 5 hrs ago
Experimental drug cleared pancreatic tumors in 75% of mice in one model
Researchers tested an experimental drug in mice to see whether it could help the immune system attack cancer.
The work, led by scientists at MedPacto in Seoul, focused on pancreatic cancer and also examined other cancers.
Some tumors build a dense, scar-like barrier that keeps cancer-fighting immune cells out, making treatments such as immunotherapy less effective.
The drug targeted a signal that helps build this barrier, aiming to block it mainly inside tumors and limit effects elsewhere.
In one aggressive pancreatic cancer model, tumors disappeared in 75% of treated mice, and seven of eight were alive 270 days after treatment ended.
Some cured mice resisted cancers they had not encountered before, suggesting the treatment may help create lasting immune protection.
The findings are from mice, not people, and the available information does not say what human testing will happen next.
Erasca plans to present new data on its experimental drug ERAS-0015 at the EORTC-NCI-AACR “Triple” meeting.
The presentation is scheduled for Friday in Barcelona.
The drug is being studied in second-line-or-later pancreatic cancer.
Erasca CEO Jonathan Lim has indicated that the overall response rate could be around 40%.
STAT said the company has so far released only limited data from an early-stage study.
- Who
- Erasca, a U.S.-based biotechnology company, is presenting the data.
- What
- It plans to present new data on ERAS-0015, a pan-RAS inhibitor.
- When
- Friday; the exact date is not stated.
- Where
- The EORTC-NCI-AACR “Triple” meeting in Barcelona.
- Why
- To present data on the drug in second-line-or-later pancreatic cancer.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- ERAS-0015
- Study setting
- Second-line-or-later pancreatic cancer
- Meeting
- EORTC-NCI-AACR “Triple
- Location
- Barcelona
- Indicated response rate
- Around 40% (a “4-handle”)
2 sources
What people are saying
meaningfully different